Respiratory disease is a huge global issue, with asthma and chronic obstructive pulmonary disease (COPD) affecting hundreds of millions globally. COPD was reported by the WHO as the third-leading cause of death worldwide in 2019, causing 3.23 million deaths, with asthma causing a further 455,500. These numbers are only expected to rise as the global population grows and ages, which is just one reason for the increasing interest in inhaled medicines.
EPM speaks to Chris Allen, CEO of scientific consultancy and Contract Research Organisation (CRO) Broughton, which has just launched a new inhalation testing service. The service is aimed at pharmaceutical companies, generic drug manufacturers looking to reformulate existing products, and device manufacturers.